An interventional study of Non-surgical treatment and Free gingival graft in Peri-implant Mucositis, sponsored by Biruni University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Biruni University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Mucositis with a site in Turkey — 4 open to participants now, 5 under way, none of them phase 3. Mucositis · Turkey.
Among the 13 studies in Mucositis with a site in Turkey, this one is one of 3 that started in 2024, is one of 8 with no phase, and was the 4th registered.
265 studies on the registry are indexed under Mucositis; 34 are open to participants now.
Browse Mucositis studies →4 of the 13 studies in Mucositis with a site in Turkey are open now. Recruiting first, the newest first:
Kutahya Health Sciences University · Sites in Turkey
Ages 18 mo+
Ege University · Sites in Turkey
Ages 6–12
Inonu University · Sites in Turkey
Ages 18–70 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 21 Mucositis studies recruiting now, 13 (62%) set no upper age limit and 7 (33%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is close to the median of 45 across 215 interventional studies indexed under Mucositis.
Median enrollment 43 across the 9 interventional studies, 86 across the 4 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
Biruni University is the lead sponsor of 183 studies on the registry; 45 are open to participants now.
Biruni University has 1 study filed under Mucositis — fewer than ten, so there is no comparison to draw.
5 of the studies in Mucositis with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06305000Biruni UniversityImpact of Keratinized Mucosa Augmentation on Treatment Outcomes of Peri-implant Mucositis | 2026-12-10 |
| NCT07828067Inonu UniversityShort Versus Standard Dental Implants: Clinical and Biomarker Outcomes | 2026-12-30 |
| NCT07785817Medipol UniversityEvaluation of aMMP-8 and IL-1β Levels and Marginal Bone Loss Associated With Peri-Implant Mucositis and Peri-Implantitis in Postmenopausal Women | 2027-02-01 |
| NCT07330609Kutahya Health Sciences UniversityClinical, Radiographic, and Digital Evaluation of the Effects of Autogenous Grafts on Peri-implant Mucosa | 2027-08-02 |
| NCT06955338Ege UniversityMusic and VR Effects on Pain, Anxiety, and Fear During Oral Mucositis Care in Leukaemic Children | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 13 studies in Mucositis with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to observe the effects of keratinized mucosa width on peri-implant tissues by evaluating clinical and biochemical parameters. The main question it aims to answer is:
Would increasing the width of the keratinized mucosa with free gingival graft (FGG) in peri-implant mucositis be beneficial in terms of clinical periodontal parameters and peri-implant crevicular fluid levels of inflammatory cytokines compared to non-surgical therapy alone?
Our study consists of 4 groups:
Peri-implant healthy group with sufficient keratinized mucosa (≥ 2mm) (n=16), peri-implant mucositis group with sufficient keratinized mucosa (n=16), peri-implant mucositis group with insufficient keratinized mucosa (\< 2mm) receiving only non-surgical treatment (n=16), peri-implant mucositis group with insufficient keratinized mucosa receiving FGG in addition to non-surgical treatment (n=16). Clinical and biochemical measurements will be recorded at the baseline, 1st month, 4th month and 7th month of the study. Peri-implant crevicular fluid samples will be collected at baseline, 1st month, 4th month and 7th month. IL-1β, RANKL, OPG levels, and RANKL/OPG ratio will be analyzed from collected samples.
Researchers will evaluate the possible benefits of FGG application in addition to non-surgical therapy by comparing the biochemical and clinical changes in areas with and without FGG application in the treatment of peri-implant mucositis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Only non-surgical therapy will apply
Procedure: Non-surgical treatment
Free gingival graft will apply following non-surgical therapy
Procedure: Non-surgical treatment · Procedure: Free gingival graft
Non-surgical treatment consists of oral hygiene instructions, full mouth supragingival scaling using titanium hand instruments, ultrasonic devices, and subgingival debridement under local anesthesia with titanium curettes and ultrasonic instruments in a single appointment.
After adequate local anesthesia is achieved. A horizontal incision is placed mucogingival junction level to prepare the recipient bed. A split-thickness flap is raised without disturbing the periosteum. FGG is obtained from the palate, extending from the mesial surface of the second premolar to the middle of the first molar. The graft is shaped and stitched on the recipient surface.
Inflammatory parameter levels in peri-implant crevicular fluid
Peri-implant crevicular fluid samples will be collected from 3 sites (mesiobuccal, buccal, distobuccal) of the implants using methylcellulose strips PerioPaper® (Oralflow Inc., Smithtown, NY, USA) gently placed into the cleansed and dried pocket for 30 sec. Interleukin-1beta, RANKL and OPG levels and RANKL/ OPG ratio will be evaluated.
Time frame: Baseline (prior to therapy)
Inflammatory parameter levels in peri-implant crevicular fluid
Peri-implant crevicular fluid samples will be collected from 3 sites (mesiobuccal, buccal, distobuccal) of the implants using methylcellulose strips PerioPaper® (Oralflow Inc., Smithtown, NY, USA) gently placed into the cleansed and dried pocket for 30 sec. Interleukin-1beta, RANKL and OPG levels and RANKL/ OPG ratio will be evaluated.
Time frame: 1st month
Inflammatory parameter levels in peri-implant crevicular fluid
Peri-implant crevicular fluid samples will be collected from 3 sites (mesiobuccal, buccal, distobuccal) of the implants using methylcellulose strips PerioPaper® (Oralflow Inc., Smithtown, NY, USA) gently placed into the cleansed and dried pocket for 30 sec. Interleukin-1beta, RANKL and OPG levels and RANKL/ OPG ratio will be evaluated.
Time frame: 4th month
Inflammatory parameter levels in peri-implant crevicular fluid
Peri-implant crevicular fluid samples will be collected from 3 sites (mesiobuccal, buccal, distobuccal) of the implants using methylcellulose strips PerioPaper® (Oralflow Inc., Smithtown, NY, USA) gently placed into the cleansed and dried pocket for 30 sec. Interleukin-1beta, RANKL and OPG levels and RANKL/ OPG ratio will be evaluated.
Time frame: 7th month
Plaque index (Silness & Löe, 1964)
0: Absence of microbial plaque 1. Thin plaque layer at the mucosal margin, only detectable by scraping with a probe 2. Moderate layer of plaque in the along the mucosal margin; interdental spaces free, but plaque is visible to naked eye 3. Abundant plaque along with the mucosal margin; interdental places filled with plaque
Time frame: Baseline (prior to therapy)
Plaque index (Silness & Löe, 1964)
Plaque index (Silness \& Löe, 1964): 0: Absence of microbial plaque 1. Thin plaque layer at the mucosal margin, only detectable by scraping with a probe 2. Moderate layer of plaque in the along the mucosal margin; interdental spaces free, but plaque is visible to naked eye 3. Abundant plaque along with the mucosal margin; interdental places filled with plaque
Time frame: 1st month
Plaque index (Silness & Löe, 1964)
0: Absence of microbial plaque 1. Thin plaque layer at the mucosal margin, only detectable by scraping with a probe 2. Moderate layer of plaque in the along the mucosal margin; interdental spaces free, but plaque is visible to naked eye 3. Abundant plaque along with the mucosal margin; interdental places filled with plaque
Time frame: 4th month
Plaque index (Silness & Löe, 1964)
0: Absence of microbial plaque 1. Thin plaque layer at the mucosal margin, only detectable by scraping with a probe 2. Moderate layer of plaque in the along the mucosal margin; interdental spaces free, but plaque is visible to naked eye 3. Abundant plaque along with the mucosal margin; interdental places filled with plaque
Time frame: 7th month
Gingival Index ( Löe & Silness,1963)
0: normal gingiva 1. mild inflammation - slight change in color and slight edema but no bleeding on probing 2. moderate inflammation - redness, edema and glazing, bleeding on probing 3. severe inflammation - marked redness and edema, ulceration with tendency to spontaneous bleeding
Time frame: Baseline (prior to therapy)
Gingival Index ( Löe & Silness,1963)
0: normal gingiva 1. mild inflammation - slight change in color and slight edema but no bleeding on probing 2. moderate inflammation - redness, edema and glazing, bleeding on probing 3. severe inflammation - marked redness and edema, ulceration with tendency to spontaneous bleeding
Time frame: 1st month
Gingival Index ( Löe & Silness,1963)
0: normal gingiva 1. mild inflammation - slight change in color and slight edema but no bleeding on probing 2. moderate inflammation - redness, edema and glazing, bleeding on probing 3. severe inflammation - marked redness and edema, ulceration with tendency to spontaneous bleeding
Time frame: 4th month
Gingival Index ( Löe & Silness,1963)
0: normal gingiva 1. mild inflammation - slight change in color and slight edema but no bleeding on probing 2. moderate inflammation - redness, edema and glazing, bleeding on probing 3. severe inflammation - marked redness and edema, ulceration with tendency to spontaneous bleeding
Time frame: 7th month
Bleeding on probing (Ainamo & Bay 1975)
Bleeding on probing A bleeding-on-probing percentage score assessed as the proportion of bleeding sites (dichotomous yes/no evaluation) when stimulated by a standardized manual probe with a controlled (\~25 g) force to the bottom of the sulcus/pocket at six sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual) on all present teeth/ implants.
Time frame: Baseline (prior to therapy)
Bleeding on probing (Ainamo & Bay 1975)
Bleeding on probing A bleeding-on-probing percentage score assessed as the proportion of bleeding sites (dichotomous yes/no evaluation) when stimulated by a standardized manual probe with a controlled (\~25 g) force to the bottom of the sulcus/pocket at six sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual) on all present teeth/ implants.
Time frame: 1st month
Bleeding on probing (Ainamo & Bay 1975)
Bleeding on probing A bleeding-on-probing percentage score assessed as the proportion of bleeding sites (dichotomous yes/no evaluation) when stimulated by a standardized manual probe with a controlled (\~25 g) force to the bottom of the sulcus/pocket at six sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual) on all present teeth/ implants.
Time frame: 4th month
Bleeding on probing (Ainamo & Bay 1975)
Bleeding on probing A bleeding-on-probing percentage score assessed as the proportion of bleeding sites (dichotomous yes/no evaluation) when stimulated by a standardized manual probe with a controlled (\~25 g) force to the bottom of the sulcus/pocket at six sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual) on all present teeth/ implants.
Time frame: 7th month
Keratinized mucosa width
The apical-coronal distance from the mucosal margin to the mucogingival junction (MGJ) Measurements will be made at three points on implants (mesiobuccal, midbuccal, distobuccal) using a periodontal probe.
Time frame: Baseline (prior to therapy)
Keratinized mucosa width
The apical-coronal distance from the mucosal margin to the mucogingival junction (MGJ). Measurements will be made at three points on implants (mesiobuccal, midbuccal, distobuccal) using a periodontal probe.
Time frame: 1st month
Keratinized mucosa width
The apical-coronal distance from the mucosal margin to the mucogingival junction (MGJ). Measurements will be made at three points on implants (mesiobuccal, midbuccal, distobuccal) using a periodontal probe.
Time frame: 4th month
Keratinized mucosa width
The apical-coronal distance from the mucosal margin to the mucogingival junction (MGJ). Measurements will be made at three points on implants (mesiobuccal, midbuccal, distobuccal) using a periodontal probe.
Time frame: 7th month
Probing depth
Probing pocket depth: The distance from the base of the pocket to the mucosal margin. Measurements will be made at six points on all teeth/ implants (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) using a periodontal probe.
Time frame: Baseline (prior to therapy)
Probing depth
Probing pocket depth: The distance from the base of the pocket to the mucosal margin. Measurements will be made at six points on all teeth/ implants (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) using a periodontal probe.
Time frame: 1st month
Probing depth
The distance from the base of the pocket to the mucosal margin. Measurements will be made at six points on all teeth/ implants (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) using a periodontal probe.
Time frame: 4th month
Probing depth
The distance from the base of the pocket to the mucosal margin. Measurements will be made at six points on all teeth/ implants (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) using a periodontal probe.
Time frame: 7th month
Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.
Of 67 non-industry interventional studies with no phase under Mucositis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 26. This study's planned 32 months is above that.
Counting every sponsor, half of 70 studies reached it within 12 months; a quarter within 6 and three quarters within 26.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.